ABI-274

CAT: 0804-HY-W674149Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-W674149Size:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
ABI-274 is a tubulin and colchicine binding site inhibitor. ABI-274 significantly promotes cancer cell apoptosis in vitro when combined with vemurafenib (HY-12057) . ABI-274 exhibits potent synergistic efficacy in the vemurafenib-resistant xenograft model in nude mice. ABI-274 can be studied in research on melanoma[1].
CAS Number
[1253697-93-6]
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Microtubule/Tubulin
Related Pathways
Cell Cycle/DNA Damage; Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
COC1=CC(C(C2=CN=C(C3=CC=C(C=C3)C)N2)=O)=CC(OC)=C1OC
Molecular Formula
C20H20N2O4
Molecular Weight
352.38
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]Wang, J., et al., (2014) . Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma. Molecular cancer therapeutics, 13 (1), 16-26.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products